Salute e Benessere

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab…

Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in...
Nasdaq GlobeNewswire
10/06/2025

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and…

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy ®(semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and real-world setting, including cardiometabolic and kidney health benefits for those with obesity and diabetesNovo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational...
Nasdaq GlobeNewswire
10/06/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from June 2 to June 6, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
10/06/2025

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of…

Dr. Lone Ottesen, Chief Medical Officer of Adcendo, said: "The dosing of the first patient in the ADCElerate1 study is a major milestone for both Adcendo and for the uPARAP program and we are excited to evaluate ADCE-D01's potential benefit for patients with advanced STS. uPARAP is a highly attractive target for the development of an ADC in mesenchymal cancers, as it is highly overexpressed in multiple STS subtypes, has unique internalization properties, and shows only very low expression…
PR Newswire
10/06/2025

Boehringer Ingelheim and Eko Health Inc. enter digital health collaboration to…

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogsIngelheim, Germany, and San Francisco, Calif., June 10, 2025| Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, have entered a strategic collaboration agreement. This collaboration brings together...
Nasdaq GlobeNewswire
10/06/2025

International Oncology Experts Meet in Kenya to Address Regional Cancer Needs

The ACS Global Academy Regional Workshop brings together oncology specialists from around the world to improve treatment and support for people with cancer. The three-day workshop includes two days devoted to updating NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) adapted specifically for the Sub-Saharan Africa region. Additional workshops will focus on improving utilization of those guidelines, navigation programs, and provider tools. The ACS Global Academy Regional…
PR Newswire
10/06/2025

Global Clinical Workflow Management Software Market Projected to Reach USD USD…

Furthermore, there's an increasing need for cloud-based platforms to manage healthcare data effectively, given the volume of patient records that require organization and accessibility. However, high costs associated with software installation and maintenance present challenges. Despite this, the future looks bright for clinical workflow management as technology continues to evolve, making healthcare more efficient and responsive to patient needs. Furthermore, there's an increasing need for...
PR Newswire
10/06/2025

New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss

ISHRS members reported continued growth in the field of hair restoration, due in large part to continual refinements in hair transplantation and a variety of effective non-surgical and medical solutions to combat hair loss. Specifically, the average number of patients per ISHRS member increased by 20% since 2021. The average number of hair restoration surgeries performed per ISHRS member per month in 2024 was 15, which reflects the hands-on nature of ISHRS physicians and their commitment to…
PR Newswire
10/06/2025

Virbac : Declaration of the number of share and voting rights 05/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsMay, 31 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
10/06/2025

Trading by management and close relations of management

Please read the announcement in PDF Attachment 2025_28_Trading_By_Management
Nasdaq GlobeNewswire
10/06/2025

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell…

ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. ALY-301 is the…
PR Newswire
10/06/2025

AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and…

AMSilk4Care is a base pure protein formulation ingredient, designed for brand owners and ingredient suppliers to test in their product formulations and unlock the full potential of silk protein in different household and personal care applications. AMSilk4Care is a base pure protein formulation ingredient, designed for brand owners and ingredient suppliers to test in their product formulations and unlock the full potential of silk protein in different household and personal care applications...
PR Newswire
10/06/2025

Company Update

DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare selected for prestigiousGrow Digital Health MidlandsProgrammeDXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme.Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands…
Nasdaq GlobeNewswire
10/06/2025

Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 10, 2025Idorsia Ltd (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as Chief Executive Officer of Idorsia, effective July 1, 2025. Srishti is uniquely placed to take the leadership of the company having served on the Board of Directors since 2021, gaining a deep understanding of the company, the people, the business, and Idorsia’s outstanding product and development portfolio.Srishti is a physician...
Nasdaq GlobeNewswire
10/06/2025

Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to…

"For too long, serious liver diseases like MASH have gone under the radar—but with MASH rates soaring alongside the global obesity epidemic, it's time to tackle liver disease head on," said Sandy Sommer, Head of the Therapeutic Area for Cardiovascular, Renal and Metabolic at Boehringer Ingelheim. "Obesity and MASH are deeply interconnected chronic diseases that no organization can tackle alone. At Boehringer, we're committed to being part of the solution, and the expansion of our…
PR Newswire
10/06/2025

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth…

Key Takeaways from the HER2+ Gastric Cancer Market Report Key Takeaways from the HER2+ Gastric Cancer Market Report Discover which therapies are expected to grab the HER2+ gastric cancer market share @ HER2+ Gastric Cancer Market Report HER2+ Gastric Cancer Overview Gastric cancer is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths worldwide. HER2, also known as HER2/neu or ERBB2, is found in approximately 15–30% of gastric…
PR Newswire
09/06/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l’Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,452,461,656 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
09/06/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments Notification of managers' transaction - T Rosenberg - June 2025 BOD grantNotification of managers' transaction - C Ackermann- June 2025 BOD grantNotification of managers' transaction - A Khanani - June 2025 BOD grantNotification of managers' transaction - R Warner - June 2025 BOD grant
Nasdaq GlobeNewswire
09/06/2025

Nontuberculous Mycobacterial (NTM) Diagnostic Market to Reach USD 3,261.1…

Browse the report and understand how it can benefit your business strategy-https://www.credenceresearch.com/report/ntm-diagnostic-market Browse the report and understand how it can benefit your business strategy- https://www.credenceresearch.com/report/ntm-diagnostic-market Key Growth Determinants: Nontuberculous Mycobacterial (NTM) Diagnostic Market The growth of the NTM Diagnostic Market is primarily driven by the rising global prevalence of NTM infections, particularly among...
PR Newswire
09/06/2025

BASTIDE : Disposal of CICADUM and MEDSOFT

Caissargues, June 9, 2025 Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned, both specialized in stomatherapy. The two subsidiaries have been sold to their founders. In 2023-2024 fiscal year, Cicadum and Medsoft generated combined…
Actusnews Wire
09/06/2025

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna…

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA's prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. OSA is the most common sleep-related breathing disorder,...
PR Newswire
09/06/2025

Patient Handling Equipment Market worth US$16.4 billion in 2030 with 5.8% CAGR |…

Browse in-depth TOC on "Patient Handling Equipment Market" Browse in-depth TOC on "Patient Handling Equipment Market" 756 - Tables52 - Figures510 - Pages By type,the patient handling equipment market is segmented based on type into patient transfer devices, medical beds, mobility equipment, bathroom & toilet assist equipment, and stretchers & transport chairs. The patient transfer devices segment will dominate the market during the forecast period. This segment...
PR Newswire
09/06/2025

SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More…

"We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection," said Pia Renaudin, CEO of SciBase. "The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care." " We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early…
PR Newswire
09/06/2025

DRIFT EXPANDS PREMIUM HOME AND CAR FRAGRANCE PRODUCTS TO CANADA, UK, AND…

"We've heard from our community around the world who want access to our elevated car and home products, and we're excited to finally bring Drift to these new regions," said Elena Lecue, Chief Marketing Officer at Drift. "Our mission is to elevate the everyday driving and living experience with simple, beautiful scent solutions—and now, more people can enjoy that no matter where they are." "We've heard from our community around the world who want access to our elevated…
PR Newswire
09/06/2025
Altri  Comunicati